The outlook is rosy for the most flexible and adaptable, pharma business leaders agree
This article was originally published in Scrip
Despite the dreaded patent cliff, spiralling costs of R&D and increasingly demanding regulatory hurdles, big pharma still has opportunities for growth and there remain huge areas of unmet medical need. But adaptability will be key, according to business leaders speaking at the FT Global Pharmaceutical and Biotechnology Conference in London on November 17-18th.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.